Patents by Inventor Takafumi Imoto
Takafumi Imoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10336708Abstract: A novel imidazole compound that yields a surface treatment liquid that is very effective at suppressing migration and oxidation of a wiring surface; a metal surface treatment liquid that contains the imidazole compound; a metal surface treatment method that uses the metal surface treatment liquid; and a laminate production method that uses the surface treatment liquid. A metal is surface-treated using the surface treatment liquid which includes a saturated fatty acid or a saturated fatty acid ester of a specific structure, in which a prescribed position is substituted by an aromatic group of a prescribed structure and an imidazolyl group that may have a substituent group.Type: GrantFiled: August 27, 2015Date of Patent: July 2, 2019Assignee: TOKYO OHKA KOGYO CO., LTD.Inventors: Tatsuro Ishikawa, Kunihiro Noda, Yasuhide Ohuchi, Hiroki Chisaka, Dai Shiota, Yukitsugu Maeda, Takafumi Imoto, Kouhei Fujita, Yasuyuki Akai
-
Publication number: 20170247334Abstract: A novel imidazole compound that yields a surface treatment liquid that is very effective at suppressing migration and oxidation of a wiring surface; a metal surface treatment liquid that contains the imidazole compound; a metal surface treatment method that uses the metal surface treatment liquid; and a laminate production method that uses the surface treatment liquid. A metal is surface-treated using the surface treatment liquid which includes a saturated fatty acid or a saturated fatty acid ester of a specific structure, in which a prescribed position is substituted by an aromatic group of a prescribed structure and an imidazolyl group that may have a substituent group.Type: ApplicationFiled: August 27, 2015Publication date: August 31, 2017Inventors: Tatsuro ISHIKAWA, Kunihiro NODA, Yasuhide OHUCHI, Hiroki CHISAKA, Dai SHIOTA, Yukitsugu MAEDA, Takafumi IMOTO, Kouhei FUJITA, Yasuyuki AKAI
-
Patent number: 9206138Abstract: Provided is a high-purity crystal of an unsaturated carboxylic acid amide compound which is useful as or for fine chemicals such as pharmaceuticals, agricultural chemicals, polymeric materials, functional materials, and intermediates of them. The crystal includes an unsaturated carboxylic acid amide compound represented by Formula (1) in an amount of 95 percent by area or more. In X-ray diffraction, the crystal exhibits peaks at 2? in the range of 29.0 to 30.0 and in at least one range selected from 6.0 to 8.0, 12.0 to 13.5, and 16.5 to 17.5 and exhibits approximately no peak at 2? in the range of 14.0 to 15.0.Type: GrantFiled: August 5, 2013Date of Patent: December 8, 2015Assignee: Daicel CorporationInventors: Yukitsugu Maeda, Takafumi Imoto, Yasuyuki Akai, Kouhei Fujita, Shinya Sahara
-
Publication number: 20150299135Abstract: Provided is a high-purity crystal of an unsaturated carboxylic acid amide compound which is useful as or for fine chemicals such as pharmaceuticals, agricultural chemicals, polymeric materials, functional materials, and intermediates of them. The crystal includes an unsaturated carboxylic acid amide compound represented by Formula (1) in an amount of 95 percent by area or more. In X-ray diffraction, the crystal exhibits peaks at 2? in the range of 29.0 to 30.0 and in at least one range selected from 6.0 to 8.0, 12.0 to 13.5, and 16.5 to 17.5 and exhibits approximately no peak at 2? in the range of 14.0 to 15.0.Type: ApplicationFiled: August 5, 2013Publication date: October 22, 2015Applicant: DAICEL CORPORATIONInventors: Yukitsugu MAEDA, Takafumi IMOTO, Yasuyuki AKAI, Kouhei FUJITA, Shinya SAHARA
-
Patent number: 7060721Abstract: Imidazole compounds represented by general formula (I): wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy inhibitory action.Type: GrantFiled: December 20, 1999Date of Patent: June 13, 2006Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noriko Oku, legal representative, Chikako Oku, legal representative, Tomohito Oku, legal representative, Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Naoki Ishibashi, Hiroyuki Setoi, Noritsugu Yamasaki, Takafumi Imoto, Takahiro Hiramura, Teruo Oku, deceased
-
Publication number: 20050171185Abstract: A novel indole derivative or a salt thereof is provided, which is represented by the formula: wherein R1 represents an aryl lower alkyl group, said aryl group may be substituted with one or more groups selected from the group consisting of a halogen atom, an aryl group, a heterocyclic group, an aryl lower alkyl group, an aryl lower alkenyl group, a halo-lower alkyl group, a lower cycloalkyl-lower alkoxy group, a lower cycloalkoxy-lower alkyl group, an aryl lower alkynyl group, an aryloxy lower alkyl group, an aryl lower alkoxy group, a lower alkylthio group, a lower alkoxy group, and an alkenyl group; and R2 represents a lower alkyl group, a lower alkenyl group, an aryl group, or a heterocyclic group, each of which may be substituted with a hydrogen atom, a lower alkyl group, a lower alkenyl group, or an aryl group. The compound of the present invention has blood sugar level-depressing activity and PDE5-inhibiting activity, and is useful as medicine.Type: ApplicationFiled: March 29, 2005Publication date: August 4, 2005Inventors: Noritsugu Yamasaki, Takafumi Imoto, Teruo Oku, Noriko Oku, Chikako Oku, Tomohito Oku, Hiroshi Kayakiri, Osamu Onomura, Takahiro Hiramura
-
Patent number: 6911469Abstract: A sulfonamide compound of the formula (I): R1—SO2NHCO—A—X—R2??(I) wherein R1 is alky, alkenyl, alkynyl and the like; A is an optionally substitutedheteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyland 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.Type: GrantFiled: January 17, 2002Date of Patent: June 28, 2005Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Tsuyoshi Mizutani, Teruo Oku, Noritsugu Yamasaki, Osamu Onomura, Masahiro Nishikawa, Takahiro Hiramura, Takafumi Imoto
-
Patent number: 6890934Abstract: The present invention relates to a sulfonamide compound of the formula (I): wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy suppressing action.Type: GrantFiled: February 10, 2003Date of Patent: May 10, 2005Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noriko Oku, Chikaka Oku, Tomohiro Oku, Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Naoki Ishibashi, Hiroyuki Setoi, Noritsugu Yamasaki, Takafumi Imoto, Takahiro Hiramura, Teruo Oku
-
Patent number: 6869950Abstract: The present invention provides novel benzimidazole derivatives of the following formula (I) and salts thereof: wherein R1 represents a lower alkyl group or a lower alkyloxy-lower alkyl group; R2 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an aryl group, and such; R3 represents a lower alkyl group, a lower alkenyl group, an aryl group, a lower alkylaryl group, an aryl-lower alkenyl group, a halothienyl group, a lower alkylamino group, or an aryl-lower alkylamino group; A represents a benzene ring, a naphthalene ring, or a pyridine ring; and X represents a halogen atom. The derivatives and their salts have blood sugar level-depressing activity or PDE5-inhibiting activity, and are useful as pharmaceutical preparations.Type: GrantFiled: December 22, 1999Date of Patent: March 22, 2005Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noritsugu Yamasaki, Takafumi Imoto, Takahiro Hiramura, Miho Kawauchi, Noriko Oku, Chikako Oku, Tomohito Oku, Hiroshi Kayakiri, Hitoshi Sawada, Teruo Oku
-
Publication number: 20040180947Abstract: A sulfonamide compound of the formula (I):Type: ApplicationFiled: March 30, 2004Publication date: September 16, 2004Applicant: Fujisawa Pharmaceutical Co., Ltd.Inventors: Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Tsuyoshi Mizutani, Teruo Oku, Noritsugu Yamasaki, Osamu Onomura, Masahiro Nishikawa, Takahiro Hiramura, Takafumi Imoto
-
Patent number: 6787565Abstract: A sulfonamide compound of the formula (I): R1—SO2NHCO—A—X—R2 (I) wherein R1 is alky, alkenyl, alkynyl and the like; A is an optionally substitutedheteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyland 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.Type: GrantFiled: January 17, 2002Date of Patent: September 7, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Tsuyoshi Mizutani, Teruo Oku, Noritsugu Yamasaki, Osamu Onomura, Masahiro Nishikawa, Takahiro Hiramura, Takafumi Imoto
-
Patent number: 6703410Abstract: 3-(2,4-Dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide, a compound having hypoglycemic activity or PDE5 inhibitory effect, has three forms of crystal forms that are distinguishable by their X-ray powder diffraction values. The most crystallographically stable crystal form is useful as a drug substance for medicines. Another crystal form can be purified efficiently by crystallization, since it forms larger crystals and can be very easily isolated by filtration. Thus this crystal form is useful for purifying 3-(2,4-Dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide.Type: GrantFiled: September 13, 2001Date of Patent: March 9, 2004Assignees: Fujisawa Pharmaceutical Co., Ltd., Daicel Chemical Industries, Ltd.Inventors: Yoshiyuki Murai, Noritsugu Yamasaki, Takafumi Imoto, Masahiro Nishikawa, Kunihiko Dohtsu
-
Publication number: 20030171396Abstract: The present invention relates to a sulfonamide compound of the formula (I): 1Type: ApplicationFiled: February 10, 2003Publication date: September 11, 2003Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Teruo Oku, Noriko Oku, Chikako Oku, Tomohito Oku, Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Naoki Ishibashi, Hiroyuki Setoi, Noritsugu Yamasaki, Takafumi Imoto, Takahiro Hiramura
-
Patent number: 6573274Abstract: The present invention relates to a sulfonamide compound of the formula (I): wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy suppressing action.Type: GrantFiled: September 12, 2001Date of Patent: June 3, 2003Assignee: Fujisawa Pharmaceutical Co. Ltd.Inventors: Teruo Oku, Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Naoki Ishibashi, Hiroyuki Setoi, Noritsugu Yamasaki, Takafumi Imoto, Takahiro Hiramura
-
Publication number: 20020099212Abstract: A sulfonamide compound of the formula (I):Type: ApplicationFiled: January 17, 2002Publication date: July 25, 2002Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Tsuyoshi Mizutani, Teruo Oku, Noritsugu Yamasaki, Osamu Onomura, Masahiro Nishikawa, Takahiro Hiramura, Takafumi Imoto
-
Patent number: 6420409Abstract: A novel benzimidazole derivative or a salt thereof is provided, which is represented by the formula: wherein R1 represents an alkyl group, etc., R2 represents a substituted or unsubstituted aromatic lower alkyl group, R3 represents an alkyl group, etc., and -X- is represented by the following formula (V): etc. This derivative or a salt thereof is useful as medicine.Type: GrantFiled: March 24, 2000Date of Patent: July 16, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noritsugu Yamasaki, Takafumi Imoto, Teruo Oku, Akira Katayama, Hiroshi Kayakiri, Osamu Onomura, Takahiro Hiramura, Masahiro Nishikawa, Hitoshi Sawada
-
Patent number: 6352985Abstract: A benzimidazole compound represented by the formula (I): wherein R3 is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.Type: GrantFiled: January 28, 2000Date of Patent: March 5, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noritsugu Yamasaki, Takafumi Imoto, Yoshiyuki Murai, Takahiro Hiramura, Teruo Oku, Kouzou Sawada
-
Patent number: 6348474Abstract: A sulfonamide compound of the formula (I): R1—SO2NHCO—A—R2 (I) wherein R1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.Type: GrantFiled: February 14, 2000Date of Patent: February 19, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Tsuyoshi Mizutani, Teruo Oku, Noritsugu Yamasaki, Osamu Onomura, Masahiro Nishikawa, Takahiro Hiramura, Takafumi Imoto
-
Patent number: 6242474Abstract: Novel aromatic ring derivatives represented by formula (I) or their pharmaceutical acceptable salts are provided. wherein Nu represents a 5- or 6-membered aromatic ring; ch1 and ch2 each represents a cross-linking group; and A represents an aromatic ring. These compounds have blood sugar-depressing activity or PDE 5 inhibitory activity and are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin-resistance, polycystic ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, hypertension, stenocardia, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, autoimmune diseases, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, nephritis, cachexia, pancreatitis, restenosis after PTCA, etc.Type: GrantFiled: March 21, 2000Date of Patent: June 5, 2001Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noritsugu Yamasaki, Takafumi Imoto, Takahiro Hiramura, Osamu Onomura, Masahiro Nishikawa, Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada
-
Patent number: 6166219Abstract: Novel benzimidazole derivatives represented by the formula (I): ##STR1## wherein R.sub.3 is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.Type: GrantFiled: November 2, 1998Date of Patent: December 26, 2000Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noritsugu Yamasaki, Takafumi Imoto, Yoshiyuki Murai, Takahiro Hiramura, Teruo Oku, Kouzou Sawada